Want the bigger research picture
This interconnection explains why anxiety reports on GLP-1 therapy vary significantly among individuals with similar doses and treatment duration
It is also worth noting that our comparison with topiramate, which shares a weight loss property, may partly reflect topiramates poor real-world tolerability and compliance rather than a true pharmacological advantage of GLP1 RAs. However, he also stated that the overall signal is encouraging and justifies further investigation
In the largest trial so far, people on retatrutide lost an average of 28.7% of their body weight over about 16 months
A., & Bisschops, J
Retatrutide and Other Metabolic Research Peptides Researchers frequently compare retatrutide with compounds such as: Tirzepatide Liraglutide GLP-1 receptor agonists Novel triple glucagon-like receptor agonists Published metabolic research by investigators including Jastreboff, Fras JP, Sanyal, Coskun, Urva, Roell WC, and Kaplan LM continues expanding interest in receptor agonist retatrutide for metabolic dysfunction-associated research